Elon Musk takes ketamine for depression and parties? The Controversial Use of Ketamine: A Potent Psychedelic Drug
Introduction:
Elon Musk, the CEO of Twitter and SpaceX, has reportedly been using small doses of the psychedelic drug ketamine to treat depression, while also consuming larger doses during social gatherings, according to a report in The Wall Street Journal. Individuals close to Musk, who claim to have witnessed his drug use, provided the information to the publication.

The report claims that Musk told his friends he "microdoses" the drug Photograph:(Reuters)
Depression Treatment with Ketamine:
The report suggests that Musk has been using ketamine, a controlled substance primarily used as an anesthetic, to address his depression. Ketamine has gained attention in recent years as a potential alternative treatment for depression, particularly for individuals who do not respond well to traditional antidepressant medications. Its fast-acting properties have shown promise in providing relief for treatment-resistant depression.
Party Occasions and Ketamine Use:
Apart from its reported therapeutic use, the article also mentions Musk's consumption of larger doses of ketamine during social events. The Wall Street Journal cites sources close to the billionaire, claiming that executives at the venture-capital firm Founders Fund, known for their investments in SpaceX and Facebook, have organized parties where psychedelics, including ketamine, are present.
Legal and Recreational Context:
Ketamine is classified as a Schedule III controlled substance in the United States, making its recreational use illegal. However, it is legally administered by medical professionals as an anesthetic and is being studied for its potential in treating depression. The presence of ketamine in social settings outside of medical supervision raises concerns about its legality and potential for misuse.
Controversies and Future Research:
The reported use of ketamine by Elon Musk has sparked debates regarding the appropriateness and safety of self-medication with psychedelics. While some proponents argue for the potential benefits of ketamine in treating depression, others emphasize the importance of further research to establish its long-term efficacy, optimal dosages, and potential risks.
Conclusion:
The reported use of ketamine by Elon Musk for depression treatment and recreational purposes has drawn attention to the ongoing discussions surrounding the use of psychedelics. While ketamine has shown potential as an alternative treatment for depression, its controlled status and potential for misuse raise concerns. Further research and regulation are necessary to fully understand its benefits, risks, and appropriate use in addressing mental health conditions.
Looking for chemical products? Let suppliers reach out to you!
2026-07-11
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Reducing to Refocus: Novo Nordisk’s 9,000-Job Cut and the Strategic Realignment in Pharma
-
Pfizer Warns Germany: Drug Pricing Could Put Investment at Risk
-
J&J VAT Dispute Threatens Free Medicine Access in Britain
-
West Asia’s Conflict Is Testing the Hidden Fragility of Pharma Trade
-
Affordable GLP-1s Could Rewrite the Global Obesity Market
-
A Cold-Chain Crackdown in Delhi Sends a Much Bigger Message
-
China’s Approval of Pfizer’s GLP-1 Drug Signals a Sharper Obesity Race
-
South Africa Wants Lenacapavir at Home, Not Just Imported
-
Torrent Pharma Targets First Wave Semaglutide Launch Revenue Up 11 Percent as Patent Ends
-
Hengrui Strikes $500 Million Global Drug Deal with GSK Potential Payouts Up to $12 Billion
Recommend Reading
-
₹27,548 Crore Pharma Giant Cipla Enters Weight Management Battle as Obesity Demand Surges
-
60 Percent Workforce Held by Top 10 Firms! China’s TCM Industry Faces Fierce Reshuffle as Private Leaders Expand Fast
-
Trump Warns of 200 Percent Tariffs on Pharma Companies by August 1 India Trade Deal Among Top Priorities
-
Emcure Seals Exclusive Deal for Sanofi’s Oral Diabetes Brands Millions of Indian Patients to Benefit
-
Over 22,000 New Cases in India AstraZeneca Gets CDSCO Green Light for Muscle-Invasive Bladder Cancer Drug
-
Supply and Demand Intensify, Acrylic Acid Market Consolidates at Low Levels
-
Supply Excess, DMF Market Shows Minor Fluctuations Amid Overall Stability
-
In early April, the price of urea in China slightly increased (4.1-4.10)
-
Melamine Prices Surge Over 10% as Upstream and Downstream Competition Intensifies in China
-
June Shandong Asphalt Market Exhibits an Overall Trend of Rising First and Then Falling